Modality
Small Molecule
MOA
KIF18Ai
Target
LAG-3
Pathway
Proteasome
GBMMG
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
~Aug 2022
→ ~Nov 2023
Phase 2
Feb 2024
→ Mar 2028
Phase 2Current
NCT08454856
2,069 pts·MG
2024-02→2028-03·Not yet recruiting
2,069 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-091.9y awayPh3 Readout· MG
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2028-03-09 · 1.9y away
MG
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08454856 | Phase 2/3 | MG | Not yet recr... | 2069 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |